Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ARMP
$10.235
$
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Next Earnings
2026-02-25
Beta
1.421
Average Volume
Market Cap
Last Dividend
CIK
0000921114
ISIN
US04216R1023
CUSIP
04216R102
CEO
Deborah L. Birx
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
60
IPO Date
1994-05-20
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 | Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product ("QIDP") for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. | PRNewsWire | 2026-02-23 07:00:00 |
| Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus | FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced the conclusion of an End-of-Phase 2 ("EOP2") written response from the U.S. Food and Drug Administration ("FDA") and plans to advance the Company's intravenously-administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. | PRNewsWire | 2026-01-13 07:00:00 |
| Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 12.8% – Still a Buy? | Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was up 12.8% during trading on Wednesday. The stock traded as high as $5.99 and last traded at $5.99. Approximately 75,815 shares traded hands during trading, a decline of 49% from the average daily volume of 148,629 shares. The stock had previously closed at $5.31. Armata | Defense World | 2025-12-04 01:50:57 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-23 | 2026-02-23 | View Filing |
| SC 13D/A | 2026-01-26 | 2026-01-26 | View Filing |
| 8-K | 2026-01-26 | 2026-01-26 | View Filing |
| 8-K | 2026-01-13 | 2026-01-13 | View Filing |
| 8-K | 2025-12-01 | 2025-12-01 | View Filing |
| 424B5 | 2025-12-01 | 2025-12-01 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-10-22 | 2025-10-22 | View Filing |
| 8-K | 2025-09-11 | 2025-09-10 | View Filing |
| EFFECT | 2025-08-25 | 2025-08-25 | View Filing |
| S-8 | 2025-08-13 | 2025-08-13 | View Filing |
| S-3 | 2025-08-13 | 2025-08-13 | View Filing |
| SC 13D/A | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 4 | 2025-07-14 | 2025-07-14 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-01 | 2025-05-01 | View Filing |
| ARS | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 3/A | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-02 | 2025-04-02 | View Filing |
| 10-K | 2025-03-21 | 2025-03-20 | View Filing |
| 8-K | 2025-03-21 | 2025-03-20 | View Filing |
| SC 13D/A | 2025-03-12 | 2025-03-12 | View Filing |
| 8-K | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2024-12-19 | 2024-12-19 | View Filing |
| 8-K | 2024-12-04 | 2024-12-04 | View Filing |
| 8-K | 2024-11-15 | 2024-11-15 | View Filing |
| SC 13D/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-10-03 | 2024-10-03 | View Filing |
| 4 | 2024-10-03 | 2024-10-03 | View Filing |
| 8-K | 2024-09-26 | 2024-09-26 | View Filing |
| 8-K | 2024-08-26 | 2024-08-26 | View Filing |
| 3 | 2024-08-19 | 2024-08-19 | View Filing |
| 8-K | 2024-08-15 | 2024-08-15 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-07-25 | 2024-07-25 | View Filing |
| 3 | 2024-06-28 | 2024-06-28 | View Filing |
| 8-K | 2024-06-14 | 2024-06-14 | View Filing |
| 10-Q | 2024-05-07 | 2024-05-07 | View Filing |
| 8-K | 2024-05-07 | 2024-05-07 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| 8-K | 2024-03-22 | 2024-03-22 | View Filing |
| 10-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| SC 13D/A | 2024-03-04 | 2024-03-04 | View Filing |
| 8-K | 2024-03-04 | 2024-03-04 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|